Coloplast AS Class B

COLO B: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|l#LOCK|bDPCLOCK|M@#q@<x

Coloplast Earnings: Reimbursement Cuts and Impairment Charges Weigh

Coloplast reported fiscal second-quarter results that featured organic revenue and operating income both growing 6% year over year. Unfavorable foreign exchange and the Kerecis impairment charge of DKK 3 billion hampered earnings.

Sponsor Center